SCHEMBL25596200

SCHEMBL25596200

CC(N)(CF)C(F)c1ccc(O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.41
ESR2 Q92731 8/20 0.41
TDP1 Q9NUW8 3/20 0.39
ALOX15 P16050 2/20 0.39
CYP2C9 P11712 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
PGR P06401 1/20 0.39
CHRM2 P08172 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
AR P10275 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD1 P21728 1/20 0.39
TBXA2R P21731 1/20 0.39
PTGS1 P23219 1/20 0.39
SLC6A2 P23975 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25596183 0.81 ESR1 (0.43) ESR1ESR2TDP1ALOX15CYP2C9
SCHEMBL22074701 0.74 ESR1 (0.41) ESR1ESR2TDP1ALOX15LMNA
SCHEMBL22074702 0.73 BLM (0.46) ESR1ESR2CYP2C9LMNAPGR
SCHEMBL25596283 0.68 ESR1 (0.55) ESR1ESR2SLC6A2CYP2C19SLC6A3
SCHEMBL26664904 0.67 ESR1 (0.45) ESR1ESR2TDP1ALOX15LMNA
SCHEMBL25596164 0.67 ESR1 (0.53) ESR1ESR2SLC6A2SLC6A3TAAR1
SCHEMBL22074748 0.66 BLM (0.42) ESR1ESR2TDP1ALOX15CYP2C9
SCHEMBL22074749 0.66 BLM (0.42) ESR1ESR2TDP1ALOX15CYP2C9
SCHEMBL9561475 0.66 ESR1 (0.52) ESR1ESR2TDP1ALOX15CYP2C9
SCHEMBL320072 0.66 ESR1 (0.54) ESR1ESR2TDP1ALOX15CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME SENDA BIOSCIENCES INC (US) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181493-A1 BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME COMT, SNCA, PARK7 ESR1 4421/4885ESR2 4494/4885TDP1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.